Renaissance Capital logo

Ventyx Biosciences Priced, Nasdaq: VTYX

Phase 1 biotech developing selective therapies for inflammatory and autoimmune diseases.

Industry: Health Care

Latest Trade: $1.74 +0.02 (+1.2%)

First Day Return: +31.4%

Return from IPO: -89.3%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. We believe our ability to discover and develop differentiated product candidates in an efficient manner allows us to address well-established multi-billion-dollar commercial markets and positions us to become a leader in the immunology market. Our lead product candidate is VTX958, an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor. Its selectivity for TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms in preclinical studies supports the potential to avoid toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors. We believe VTX958 has the potential to address a broad range of immune-mediated diseases, such as psoriasis, inflammatory bowel disease (IBD), psoriatic arthritis and lupus, each of which represent multi-billion-dollar market opportunities. We plan to develop VTX958 initially for psoriasis, psoriatic arthritis and Crohn’s disease, among other potential indications.
more less
IPO Data
IPO File Date 09/29/2021
Offer Price $16.00
Price Range $15.00 - $17.00
Offer Shares (mm) 9.5
Deal Size ($mm) $152
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/20/2021
Offer Price $16.00
Price Range $15.00 - $17.00
Offer Shares (mm) 9.5
Deal Size ($mm) $152
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Jefferies
Evercore ISI
more
Company Data
Headquarters Encinitas, CA, United States
Founded 2018
Employees at IPO n/a
Website www.ventyxbio.com

Ventyx Biosciences (VTYX) Performance